Clinuvel Pharmaceuticals Ltd revenue

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Clinuvel Pharmaceuticals Ltd: revenue history, annual

Fiscal year	2024Jun 2024	2025Jun 2025	2026Jun 2026
Revenue	58	61	64
Growth on the year before	—	+5.5%	+5.2%
Gross profit	47	50	53
Gross margin	81.5%	81.2%	82.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Clinuvel Pharmaceuticals Ltd	$64.3m	5.2%	—
Abcellera Biologics Inc.	$66.2m	101.3%	-23.0%
Cytokinetics Inc	$67.7m	-21.1%	89.5%
Recursion Pharmaceuticals, Inc.	$68.2m	56.2%	12.9%
Intellia Therapeutics, Inc.	$59.5m	12.6%	3.9%
Fennec Pharmaceuticals Inc.	$59.2m	77.8%	566.5%

Compare with peers

• Abcellera Biologics Inc. revenue
• Cytokinetics Inc revenue
• Recursion Pharmaceuticals, Inc. revenue
• Intellia Therapeutics, Inc. revenue
• Fennec Pharmaceuticals Inc. revenue

Head to head: ABCL vs CUVLCUVL vs CYTKCUVL vs RXRXCUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Clinuvel Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clinuvel Pharmaceuticals Ltd.